Pancreatic Adenocarcinoma Clinical Trials

35 studies are recruiting for pancreatic adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clearview Cancer Institute, Huntsville, Alabama

   Locations

   48 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

2. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

3. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

4. Evaluating Novel Therapies in ctDNA Positive GI Cancers

   This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (CRC, gastric, PDAC, and HCC/intra-hepatic-/extra-hepatic-, gall bladder adenocarcinomas) diagnosed with histologically confirmed GI cancers.…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia

   Locations

   3 in total

   Run by

   Georgetown University

   See if you can join NCT05482516 on ClinicalTrials.gov

5. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic - Scottsdale, Phoenix, Arizona

   Locations

   49 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07491445 on ClinicalTrials.gov

6. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

   Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tel…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California Irvine Medical Center, Orange, California

   Locations

   46 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT05365581 on ClinicalTrials.gov

7. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

   The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   The University of Arizona Cancer Center-North Campus, Tucson, Arizona

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07621718 on ClinicalTrials.gov

8. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the efficacy of combination therapy with two investigational RAS(ON) inhibitors (daraxonrasib and zoldonrasib) compared to chemotherapy.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07805954 on ClinicalTrials.gov

9. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

   The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   31 in total

   Run by

   Pfizer

   See if you can join NCT07090499 on ClinicalTrials.gov

10. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    25 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT05245500 on ClinicalTrials.gov

11. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Gilbert, Arizona

    Locations

    23 in total

    Run by

    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

12. Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

    This is a multi-center clinical study enrolling up to 50 participants. The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done …

    Stage

    Not phased

    Ages

    18 to 120

    Site

    Banner MD Anderson Cancer Center, Gilbert, Arizona

    Locations

    15 in total

    Run by

    Alpha Tau Medical LTD.

    See if you can join NCT06698458 on ClinicalTrials.gov

13. Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

    This is a phase 1, first in human, dose escalation study for safety and feasibility of multi-dose dendritic cell (DC) therapy for pancreatic ductal adenocarcinoma (PDAC) including adenosquamous carcinoma administered after surgical resection of PDAC.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas

    Locations

    3 in total

    Run by

    Diakonos Oncology Corporation

    See if you can join NCT04157127 on ClinicalTrials.gov

14. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach. This study is in 2 parts. In both parts of the study, ASP5…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UAB Medicine - UAB Hospital, Birmingham, Alabama

    Locations

    17 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT07488676 on ClinicalTrials.gov

15. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Community Cancer Institute, Clovis, California

    Locations

    47 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT04895709 on ClinicalTrials.gov

16. Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

    The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    USC Norris Comprehensive Cancer Center, Los Angeles, California

    Locations

    15 in total

    Run by

    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    See if you can join NCT05985655 on ClinicalTrials.gov

17. TCR1188-ABC Cells in KRAS-mutated Cancers

    This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers. Initially, patients with KRAS G12V mutation positive metastatic pancreatic adenocarcinoma, cholangiocarcinoma, color…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    University of Pennsylvania

    See if you can join NCT07594067 on ClinicalTrials.gov

18. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    62 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT05208762 on ClinicalTrials.gov

19. Pancreatic Cancer Detection Consortium

    This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Translational Genomics Research Institute, Phoenix, Arizona

    Locations

    11 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06388967 on ClinicalTrials.gov

20. Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

    The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and overall survival. The purpose is to advance the evidence-base for incorporat…

    Stage

    Not phased

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT01365169 on ClinicalTrials.gov

21. Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

    Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite its demonstrated potential, immunotherapy is no…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    University of Florida, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT05000294 on ClinicalTrials.gov

22. MyCap Mobile Application for Tracking Time Burden of Treatment for Patients With Pancreatic Cancer

    This clinical trial tests the feasibility of using the MyCap mobile application (app) for tracking time burden from treatment for patients with pancreatic cancer. Pancreatic cancer is best treated with many care teams, such as medical oncology and surgery, requiring patients to dedicate significant…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Ohio State University Comprehensive Cancer Center

    See if you can join NCT07619391 on ClinicalTrials.gov

23. Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

    This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe, tolerable, and helpful for people with advanced pancreatic cancer. All partici…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06483555 on ClinicalTrials.gov

24. Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma

    Advanced pancreatic cancer patients receiving treatment of adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant defactinib plus avutometinib will have increased progression-free survival (PFS) compared to historical PFS rates for patients receiving adaptive SBRT alone.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07126158 on ClinicalTrials.gov

25. A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

    This is a single arm phase II study. All patients will receive 3 cycles of the treatment of nab-paclitaxel (Days 1, 8 and 15), gemcitabine (Days 1, 8 and 15), and TTFields (worn every day for at least 18 hours). Following the initial 3 cycles of gemcitabine/nab-paclitaxel/TTFields treatment, patien…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ohio State University Comprehensive Cancer Center, Columbus, Ohio

    Run by

    Ashish Manne

    See if you can join NCT05624918 on ClinicalTrials.gov